Impact of coronary artery disease and percutaneous coronary intervention on outcomes in patients with severe aortic stenosis undergoing transcatheter aortic valve implantation

医学 传统PCI 经皮冠状动脉介入治疗 心脏病学 狭窄 冠状动脉疾病 内科学 相伴的 外科 主动脉瓣狭窄 主动脉瓣 冲程(发动机) 心肌梗塞 机械工程 工程类
作者
Peter Wenaweser,Thomas Pilgrim,Ênio Eduardo Guérios,Stefan Stortecky,Christoph Huber,Ahmed A. Khattab,Alexander Kadner,Lutz Buellesfeld,Steffen Gloekler,Bernhard Meier,Thierry Carrel,Stephan Windecker
出处
期刊:Eurointervention [European Association of Percutaneous Cardiovascular Interventions]
卷期号:7 (5): 541-548 被引量:151
标识
DOI:10.4244/eijv7i5a89
摘要

Coronary artery disease (CAD) is frequently present in patients with severe aortic stenosis (AS) undergoing transcatheter aortic valve implantation (TAVI). While revascularisation affects peri-operative outcome in patients undergoing surgical aortic valve replacement, the impact of percutaneous coronary intervention (PCI) in patients undergoing TAVI is not well established.Consecutive patients with severe AS undergoing TAVI were prospectively included into the Bern TAVI registry. In patients with CAD, myocardium at risk was assessed using the DUKE myocardial jeopardy score. Revascularisation was performed by means of PCI either staged or concomitant at the time of TAVI. Among 256 patients undergoing TAVI, 167 patients had CAD and 59 patients underwent either staged (n=23) or concomitant (n=36) PCI. Clinical outcome at 30 days was similar for patients undergoing isolated TAVI as compared with TAVI combined with PCI in terms of death (5.6% versus 10.2%, p=0.24), major stroke (4.1% versus 3.4%, p=1.00), and the VARC combined safety endpoint (31.0% versus 23.7%, p=0.33). A stratified analysis of outcomes according to presence of CAD or revascularisation showed no difference during long-term follow-up (log rank p=0.16).CAD is frequent among patients with severe AS undergoing TAVI. Among carefully selected patients, revascularisation by means of PCI can be safely performed in addition to TAVI either as a staged or a concomitant intervention.

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
午午午午完成签到 ,获得积分10
1秒前
刻苦剑封发布了新的文献求助10
1秒前
1秒前
活泼万天完成签到,获得积分10
2秒前
花鸟风月evereo完成签到,获得积分10
2秒前
4秒前
4秒前
5秒前
小二郎应助小c采纳,获得10
6秒前
南风完成签到 ,获得积分10
7秒前
三岁完成签到,获得积分10
8秒前
8秒前
8秒前
白石杏完成签到,获得积分10
9秒前
林千万完成签到,获得积分10
10秒前
忧虑的代容完成签到,获得积分10
11秒前
丘比特应助Bella采纳,获得30
14秒前
我不吃饭了完成签到,获得积分10
14秒前
曹梓聪完成签到,获得积分10
15秒前
文艺鞋子发布了新的文献求助10
15秒前
干净的琦应助科研通管家采纳,获得10
16秒前
无极微光应助科研通管家采纳,获得20
16秒前
天天快乐应助科研通管家采纳,获得10
16秒前
无极微光应助科研通管家采纳,获得20
16秒前
王迪应助科研通管家采纳,获得10
16秒前
JamesPei应助科研通管家采纳,获得10
16秒前
16秒前
Lucas应助科研通管家采纳,获得10
16秒前
16秒前
CodeCraft应助科研通管家采纳,获得10
16秒前
17秒前
17秒前
17秒前
17秒前
17秒前
酷波er应助科研通管家采纳,获得10
17秒前
王迪应助科研通管家采纳,获得10
17秒前
丘比特应助科研通管家采纳,获得10
17秒前
彭于晏应助科研通管家采纳,获得30
17秒前
今后应助科研通管家采纳,获得10
17秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
Modern Epidemiology, Fourth Edition 5000
Handbook of pharmaceutical excipients, Ninth edition 5000
Digital Twins of Advanced Materials Processing 2000
Weaponeering, Fourth Edition – Two Volume SET 2000
Social Cognition: Understanding People and Events 1000
Polymorphism and polytypism in crystals 1000
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 纳米技术 有机化学 物理 生物化学 化学工程 计算机科学 复合材料 内科学 催化作用 光电子学 物理化学 电极 冶金 遗传学 细胞生物学
热门帖子
关注 科研通微信公众号,转发送积分 6029737
求助须知:如何正确求助?哪些是违规求助? 7702032
关于积分的说明 16190968
捐赠科研通 5176833
什么是DOI,文献DOI怎么找? 2770285
邀请新用户注册赠送积分活动 1753660
关于科研通互助平台的介绍 1639323